Methods of treating muscular dystrophy
AssigneeSarepta Therapeutics, Inc.
InventorLouise RODINO-KLAPAC
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods of treating muscular dystrophy in a subject in need thereof. In certain aspects, the method comprises administering an AAV vector, e.g., an AAVrh74 vector, and an enzyme that cleaves IgG to the subject.
Claims47
A method of treating a subject having a muscular dystrophy, comprising administering to the subject in need thereof a recombinant AAVrh74 viral vector and an enzyme that cleaves immunoglobulin G (IgG);
- wherein the recombinant AAVrh74 viral vector comprises a genetic cassette encoding a therapeutic molecule.
(canceled)
-7. (canceled)
(canceled)
(canceled)
-15. (canceled)
(canceled)
(canceled)
-25. (canceled)
A method of treating a subject having a muscular dystrophy, comprising administering to the subject a recombinant AAVrh74 viral vector, wherein the subject has been previously administered an enzyme that cleaves IgG.
(canceled)
A method of preparing a subject for a gene therapy for a muscular dystrophy comprising administering to the subject an enzyme that cleaves IgG prior to administration of a recombinant AAVrh74 viral vector.
-42. (canceled)
-46. (canceled)
(canceled)
-53. (canceled)
-58. (canceled)
-62. (canceled)
-66. (canceled)
The method of claim 66, wherein the therapeutic polypeptide is a microdystrophin, a beta sarcoglycan, an alpha sarcoglycan, or any combination thereof.
-74. (canceled)
(canceled)
-86. (canceled)
-136. (canceled)
Dependencies are inferred from the claim text.